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Analysis of survival and prognostic factors in patients 
with cutaneous melanoma after therapeutic lymphadenectomy
Andrzej Pieƒkowski1, Zbigniew I. Nowecki1, Piotr Rutkowski1, Ma∏gorzata Symonides2,
W∏odzimierz Ruka1
The a i m of the study was to perform a single-institution analysis of factors influencing the clinical outcomes of cutaneous
melanoma (CM) patients undergoing therapeutic lymphadenectomy (LND). 
Pa t i e n t s  a n d  m e t h o d s.  The data of 353 consecutive melanoma patients with metastases to regional lymph nodes who
underwent radical LND from 1985 to 2001 was analyzed. For statistical analysis 10 clinico-pathological factors were chosen:
gender, primary lesion thickness (Breslow), CM level of invasion (Clark), ulceration of CM, CM site, number of metastastatic
lymph nodes, maximal diameter of metastatic lymph node(s), presence of nodal extracapsular invasion, percentage of
metastatic nodes in comparison to all dissected nodes, type of nodal metastases: macrometastases (defined as clinically detected
metastases confirmed cytologically) vs. micrometastases (positive nodes as a result of sentinel lymph node biopsy in non-
palpable regional basin). Additionally, we evaluated the influence of adjuvant radiotherapy. Survival time was calculated from
the date of LND. Median follow-up time was 27 months for survivals.
R e s u l t s.  Estimated 5-year overall survival (OS) ratio was 44% and 5-year disease free survival (DFS) rate was 35%. The
independent predictors of poor OS according to multivariate analysis were: extracapsular melanoma invasion (p<0.0001),
primary lesion Breslow thickness >3mm (p= 0.007), male sex (p=0.011) and CM site in head/neck region (p=0.05).  The
negative factors for DFS were: nodal extracapsular melanoma extension (p<0.0001) and male sex (p<0.0001). There were
no significant differences in OS and DFS for patients treated or not with adjuvant radiotherapy, although patients undergoing
adjuvant radiotherapy as a selective group demonstrated worse prognostic factors.
C o n c l u s i o n s.  The most important single factor influencing patient outcome after therapeutic lymphadenectomy due to
regional basin lymph node metastases is nodal extracapsular extension of melanoma cells.
Ocena prze˝yç i czynników rokowniczych u chorych na czerniaka skóry 
po leczniczej limfadenektomii
C e l e m  pracy by∏a jednooÊrodkowa analiza czynników wp∏ywajàcych na wyniki leczenia chorych na czerniaka, poddanych
leczniczej limfadenektomii (LND)
C h o r z y  i m e t o d y.  Poddano analizie dane 353 kolejnych chorych z przerzutami do regionalnych w´z∏ów ch∏onnych, u któ-
rych wykonano radykalnà LND w latach 1985-2001. Do analizy statystycznej w∏àczono 10 czynników rokowniczych: p∏eç pa-
cjenta, gruboÊç nacieku zmiany pierwotnej, mierzona w milimetrach, poziom naciekania zmiany pierwotnej wed∏ug skali
Clark’a, wyst´powanie bàdê brak owrzodzenia ogniska pierwotnego, stwierdzone w badaniu histopatologicznym, umiejscowie-
nie ogniska pierwotnego, liczb´ w´z∏ów ch∏onnych zaj´tych przez przerzuty, najwi´kszy wymiar najwi´kszego obj´tego przerzu-
tem w´z∏a ch∏onnego lub konglomeratu w´z∏ów ch∏onnych, stwierdzenie lub brak nacieku poza torebkà w´z∏a ch∏onnego, od-
setek obj´tych przez przerzuty w´z∏ów ch∏onnych w stosunku do ca∏kowitej przebadanej liczby w´z∏ów ch∏onnych w prepara-
cie pooperacyjnym, typ przerzutu do w´z∏a lub w´z∏ów ch∏onnych: makroprzerzut (wykryty na podstawie badania klinicznego,
potwierdzony przedoperacyjnie wynikiem cytologicznym punkcji cienkoig∏owej), vs mikroprzerzut (przerzut do w´z∏a ch∏on-
nego, stwierdzony na podstawie wyniku badania histopatologicznego usuni´tego w´z∏a wartowniczego). Dodatkowo w ana-
lizie statystycznej uwzgl´dniono wp∏yw uzupe∏niajàcej radioterapii. Czas prze˝ycia obliczano od daty limfadenektomii. Media-
na czasu obserwacji dla ˝yjàcych wynios∏a 27 miesi´cy.
W y n i k i.  Oszacowany odsetek 5-letnich prze˝yç ca∏kowitych wyniós∏ 44%, a 5-letnich prze˝yç wolnych od nawrotu choroby
– 35%. Analiza wielowariantowa wykaza∏a, ˝e istotny niekorzystny wp∏yw na prze˝ycia ca∏kowite majà: wyst´powanie
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Introduction
The incidence of cutaneous melanoma has been increa-
sing throughout the recent years. The most important
factor determining the prognosis of melanoma patients is
regional lymph node involvement (stage III according to
the American Joint Committee on Cancer – AJCC 2002)
[1]. However, the detailed contemporary analyzes of
factors influencing clinical outcome in such a group of
patients are rare in literature. The risk of disease
recurrence in patients after therapeutic lymphadenectomy
(LND) is high and ranges from 50% to 70% [2]. Similarly,
the survival analysis cumulates the subsets of patients
with 5-year survival rates from 24% to 69% [3]. This
group of patients may profit significantly from finding
new experimental, adjuvant treatment. Thus the main
problem is to find the criteria, which may identify patients
with a high risk of dissemination and unfavorable
outcome i.e. those that may benefit from adjuvant
treatment.
The main aim of this study was to perform a large,
retrospective single-institution analysis of factors influ-
encing the clinical outcomes of stage III melanoma
patients undergoing therapeutic lymph node dissection.
We analyzed the spectrum of possible and established
prognostic factors in relation to overall and disease free
survival after radical lymph node dissection. We have also
made an effort to analyze the value of adjuvant treatment
with radiotherapy.
Material and methods
Between 12/1985 and 12/2000 374 consecutive patients with
histologically proven cutaneous melanoma and regional lymph
node metastases underwent radical therapeutic lymphadenec-
tomy at the M. Sklodowska-Curie Memorial Cancer Centre and
Institute of Oncology, Warsaw, Poland.
For purpose of the analysis all patients had to meet the
following criteria:
– stage III melanoma (according to AJCC 2002) with regional
nodal metastases detected by lymphatic mapping and sentinel
node (SLN) biopsy (91 patients) or clinically and cytologically
confirmed (262 patients);
– metastases to only one regional basin;
– absence of distant and in-transit metastases;
– nformed consent.
In the group of 374 patients, 21 cases were excluded from
the analysis (5.6%), due to simultaneous therapeutic LND
performed in two basins (14 cases) or elective lymphadenectomy
(7 patients). All in all the analyzed group consisted of 353
patients, who fulfilled the presented criteria. The initial clinico-
pathological stage of melanoma was determined by pathological
evaluation of the primary lesion and dissected lymph nodes, as
well as by physical examination and routine imaging exami-
nations (chest X-ray, ultrasonography of the abdominal cavity).
Patient characteristics are summarized in Table 1. In the
analyzed group the median Breslow thickness of the primary
tumor was 4 mm (in the SLN biopsy group and clinically and
cytologically confirmed metastatic group: 3.8 mm and 4.9 mm,
respectively). Primary tumor ulceration was distributed equally
in both groups. In 91 analyzed patients the original procedure
consisted of lymphatic mapping (corresponding to 18.6% of all –
both positive and negative – SLN biopsies). We performed
preoperative lymphoscintygraphy combined with intraoperative
vital blue-dye [Patent Blau V®] lymphatic mapping and intra-
operative lymphoscintygraphy with a hand-held gamma-detecting
probe [Neoprobe 1000®, Neoprobe Corp., Dublin, OH, USA
or Navigator®, RMD Watertown, MA, USA]. During routine
pathologic examination SLNs were cut serially along the major
axis and HE stained. Paraffin embedded specimens were
examined in light microscopy (x40; x200). In doubtful cases
additional immunohistochemical staining (S 100, HMB 45) was
performed. Final pathological examination after LND revealed
extracaspular extensions of melanoma cells in 37.4% cases
(34/91) of involved lymph nodes in patients with positive SLN
biopsy and in 56.5% cases (148/262) after LND due to clinically
detected metastases.
The clinical and pathological parameters examined for
prognostic value were: primary lesion thickness according to
Breslow (≤3 mm vs 3-8 mm vs ≥8 mm), primary tumor level of
invasion according to Clark, ulceration of primary tumor,
primary lesion site (trunk vs. extremities vs. head/neck), gender,
presence of nodal extracapsular invasion, percentage of meta-
static nodes in comparison to all dissected nodes, maximal
diameter of metastatic nodes, number of metastatic nodes (1 vs
2-3 vs ≥4), type of nodal metastases: macrometastases (defined
as clinically detected metastases confirmed cytologically) vs.
micrometastases (defined as positive result of sentinel lymph
node biopsy in non-palpable regional basin).
Median follow-up time was 27 months for survivors.
Overall survival (OS) time was calculated from the date of LND
to the date of the most recent follow-up or death. Similarly,
disease-free survival (DFS) time was estimated from the date of
lymph node dissection to the date of the most recent follow-up
or disease recurrence. For survival analysis the Kaplan-Meier
method in combination with the log-rank test was used for
univariate analysis. Cox’s proportional hazard regression model
was used for multivariate analysis for variables with p≤0.1 in
univariate analysis. Contingency tables were analyzed by the
chi-square test. Differences were considered statistically
significant if p-values were <0.05. Additionally (non-randomly)
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nacieku poza torebkà w´z∏a ch∏onnego (p<0,0001), gruboÊç nacieku zmiany pierwotnej >3 mm (p=0,007), p∏eç m´ska
(p=0,011) i umiejscowienie ogniska na g∏owie lub szyi (p=0,05). Natomiast w odniesieniu do prze˝yç bezobjawowych
istotnymi i niezale˝nymi niekorzystnymi czynnikami rokowniczymi sà: stwierdzenie nacieku poza torebkà w´z∏a ch∏onnego
(p<0,0001), p∏eç m´ska (p<0,0001). Oceniajàc skutecznoÊç uzupe∏niajàcego napromieniania nie stwierdzono istotnych
statystycznie ró˝nic w prze˝yciach ca∏kowitych i bezobjawowych mi´dzy grupami chorych leczonych i nie leczonych tà
metodà, pomimo tego, ˝e napromieniana grupa chorych charakteryzowa∏a si´ gorszymi czynnikami rokowniczymi.
W n i o s k i.  Najistotniejszym pojedynczym czynnikiem wp∏ywajàcym na wyniki leczenia chorych na czerniaka po limfadenekto-
mii terapeutycznej z powodu przerzutów do w´z∏ów ch∏onnych regionalnego sp∏ywu jest obecnoÊç nacieku pozatorebko-
wego.
Key words: cutaneous melanoma, lymphadenectomy, extracapsular invasion, lymph node, radiotherapy, prognosis
S∏owa kluczowe: czerniak skóry, limfadenektomia, naciek pozatorebkowy, w´ze∏ ch∏onny, radioterapia, rokowanie
we evaluated the influence of adjuvant radiotherapy using Cox’s
model for multivariate analysis.
Results
The 5-year overall survival (OS) rate (± standard error)
of the entire group of melanoma patients (computed
from the date of lymph node dissection) was 44% (±4%).
In an univariate analysis the following factors were found
to have significant negative impact on OS: presence of
extracapsular tumor extension from involved lymph nodes
(p<0.001) [Figure 1], male gender (p=0.05), primary
tumor site on the trunk or in the head/neck region
(p=0.02), primary melanoma thickness > 3 mm (p=0.01),
number of metastatic lymph nodes >1 (p=0.007),
percentage of involved nodes >12% (p=0.001) and
macrometastases (p=0.007). No significant correlations
were found between OS and primary tumour ulceration,
Clark level or maximal diameter of metastatic nodes.
Multivariate analyses disclosed that the following
factors had an independent, negative impact on overall
survival in stage III melanoma patients: extracapsular
melanoma invasion of fat tissue surrounding metastatic
lymph nodes (p<0.0001), primary tumor thickness
> 3 mm (p=0.007), male sex (p=0.011) and head/neck
primary tumor location (p=0.04) (Table II).
Table II. Predictive factors influencing the OS of the entire group of
patients according to multivariate analysis
Variable DF Wald P Risk
Extracapsular extension 1 16.703 <0.0001 2.404
Breslow thickness > 3mm 1 7.344 0.007 1.470
Male gender 1 6.408 0.011 1.776
Primary site (extremity) 2 5.853 0.054 1.000
Primary site (head/neck) 1 4.324 0.038 2.847
Primary site (trunk) 1 3.236 0.072 1.492
209
Table I. Patient characteristics
Variable No = 353
Demographical
Gender:
female 182 (52%)
male 171 (48%)
Age:
range (min, max) (19, 87)
mean (standard deviation SD) 54 (15)
median 53
Clinical
Primary site:
extremities 182 (52%)
trunk 134 (38%)
head/neck 17 (4.5%)
unknown 20 (5.5%)
Maximal diameter of metastatic nodes:
≤3cm 239 (68%)
>3cm 103 (29%)
data not available 11 (3%)
Microstaging of primary lesion
Clark level of invasion:
I+II 39 (11%)
III 114 (32%)
IV 76 (22%)
V 70 (20%)
data not available 54 (15%)
Ulceration of primary tumor:
present 140 (40%)
absent 109 (31%)
data not available 104 (29%)
Breslow thickness:
≤ 1mm 19 (5%)
> 1 – 2≤ 29 (8%)
> 2 – 4≤ 62 (18%)
> 4 144 (41%)
data not available 99 (28%)
Microstaging of lymph nodes
Number of metastatic nodes
1 node 136 (39%)
2-3 nodes 98 (28%)
4 and more nodes 117 (32.5%)
data not available 2 (0.5%)
Percentage of metastatic nodes:
≤12% 124 (35%)
12-31% 116 (33%)
>31% 111 (31.5%)
data not available 2 (0.5%)
Type (burden) of nodal metastases:
micrometastases (positive SLN biopsy) 91 (26%)
macrometastases (clinically and cytologically 
detected) 262 (74%)
Extracapsular invasion:
present 182 (52%)
absent 169 (47.5%)
data not available 2 (0.5%)
Treatment
Lymphadenectomy:
cervical 20 (5%)
axillary 171 (49%)
inguinal 29 (8%)
ilio-inguinal 81 (23%)
ilio-obturatory-inguinal 52 (15%)
Adjuvant radiotherapy:
yes 82 (23%)
no 271 (77%)
Figure 1. Overall survival according to the presence of extracaspular
extension of nodal metastases
The 5-year disease free survival (DFS) rate was 35%
(±3%). The following factors significantly negatively
influenced DFS in univariate analysis (calculated from
the date of lymphadenectomy to the date of relapse):
male sex (p=0.019), primary tumor non-extremity
localization (p=0.05), primary tumor thickness >3 mm
(p=0.02), primary tumor Clark level >III (p=0.008),
presence of extracapsular invasion in involved lymph
nodes (p<0.001), percentage of involved nodes >12%
(p<0.001), number of metastatic lymph nodes >1
(p<0.001), and macrometastases (p=0.02). In multi-
variate analysis, only nodal extracapsular extension
(p<0.0001) and male gender (p<0.0001) correlated inde-
pendently with poorer disease-free survival (Table III).
Table III. Predictive factors influencing the DFS of the entire group of
patients according to multivariate analysis
Variable DF Wald P Risk
Extracapsular extension 1 21.808 <0.0001 2.272
Male gender 1 13.361 <0.0001 1.897
Breslow thickness >3 mm 1 2.923 0.087 1.220
Taking into account the fact, that most of the other
authors and the new AJCC 2002 staging classification do
not analyze the presence of extracapsular invasion of
melanoma cells in nodal metastases, which seems to be
the strongest prognostic factor in our analysis, we
performed a simulation of multivariate analysis for OS
after excluding this parameter. Negative, statistically
important (p<0.01) factors for OS were: male gender,
Breslow thickness >3mm, the number of metastatic nodes
>1, primary tumor site on the trunk and macrometa-
stases. Moreover, analyzing the prognostic significance
of the number of metastatic nodes and the presence of
extracapsular extension, we found that these features are
dependent on each other: the more metastatic nodes the
higher the risk of extracapsular extension (Table IV).
Table IV. Correlations between the number of metastatic nodes and
the presence of extracapsular extension
Number of metastatic nodes Extracapsular extension
of melanoma cells
No Yes Total
1 93 43 136
(55.0%) (23.7%) (39.0%)
2-3 51 47 98
(30.2%) (25.8%) (28.0%)
>3 25 92 117
(14.8%) (50.5%) (33.0%)
We also performed a separate analysis of the
outcome of patients treated (RTH/+/) or not (RTH/-/)
with adjuvant radiotherapy after lymphadenectomy. We
have not found significant differences in OS and DFS
between these two groups of patients. Therefore, we
evaluated the distribution of those prognostic variables,
which were found to be important in the above-
mentioned analyses. We have found that patients treated
with adjuvant radiotherapy had a significantly higher rate
of extracapsular extension (89%) as compared to patients,
who were not irradiated (41%) (p<0.001). In patients
undergoing radiotherapy the primary tumor was more
frequently situated in the head/neck region (9%), as
compared to patients not treated with radiotherapy
(3.5%) (p=0.005). It could be concluded, that the group
of patients with adjuvant radiotherapy demonstrated
worse prognostic factors. Thus we decided to compare
OS and DFS in the subgroup of patients treated or not
with radiotherapy, who were characterized by extra-
caspular extension within the metastatic nodes. We found
that the OS time was longer for the RTH/+/ group, as
compared with the RTH/-/ group (41% versus 22%, not
significant statistically – n.s.) (Figure 2). Similarly in the
case of DFS the curves estimated for patients with
extracapsular extension of melanoma cells have shown
significant differences between the RTH/+/ and the
RTH/-/ groups with a significant benefit discernible for the
former (28% versus 12%, n.s.).
Discussion
Our one-institution study presents a remarkable homo-
genous group of 353 patients with melanoma metastases
to regional lymph nodes as all of whom were operated on
by the same staff of surgeons. This implies that the
presented results are reliable and comparable with other
large studies [2-10].
The presence of metastases to regional lymph nodes
is one of the most important factors negatively affecting
the clinical outcome of patients with cutaneous me-
lanoma. This heterogeneous group of patients (although
generally with poor outcomes) cumulates cases with very
different prognosis (5-year survival rate ranges from 24%
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Figure 2. Overall survival in patients with extracapsular invasion
treated (rth+) or not (rth-) with adjuvant radiotherapy
to 69%). This is the reason for searching for factors,
which may help in the selection of high- and low-risk
patients.
The results of the study demonstrate that extra-
capsular extension of melanoma cells in lymph nodes is
the strongest single factor negatively influencing the
prognosis of stage III patients, both in univariate and
multivariate analysis for overall and disease-free survival.
This hypothesis is supported by the observation of
Cascinnelli et al., who showed that the presence of
metastatic melanoma cells into soft tissue adjacent to the
lymph node is a more important prognostic factor than
the number of metastatic nodes [10]. This factor was
included into the new revised AJCC staging system for
melanoma, however its role is unclear and underesti-
mated. According to a multivariate analysis after the
exclusion of this variable (which seems to be related to the
number of metastatic nodes) the most important negative
prognostic factors become the metastases to more than
one node and clinically detected macrometastases. In
most of the studies the authors did not include the
extracapsular extension for prognostic analyses [3, 4, 7, 8],
which has contributed to the reinforcement of the clinical
importance of these two other factors. The results of this
study suggest that in case of nodal extracapsular extension
the relevance of detecting melanoma metastases by
sentinel node biopsy or clinically/cytologically is similar.
The survival value of sentinel lymph node biopsy can be
proven only in prospective, randomized trials [11]. The
other issue is the determination of the compartmentation
of the number of metastatic nodes in relation to patient
survival. We suggest that the dichotomization of this
parameter in two subgroups: one metastatic node versus
more than one nodal metastases is the most effective
method and simpler than that proposed by Balch [3].
Moreover, it has been proven that the size of the
metastases is not a useful factor for prognosing survival in
melanoma patients. This factor has been eliminated from
the current staging system, while the number of involved
lymph nodes has been included [1] as the crucial factor.
Another interesting hypothesis analyzed in this study
is the prognostic value of the percentage of metastatic
nodes in relation to the total number of dissected and
pathologically evaluated nodes. This parameter, rarely
presented in the literature [10,12], has shown its
prognostic significance both for overall and disease-free
survival in an univariate analysis. The percentage of
metastatic nodes may characterize the quality of the
surgical procedure as well as the postoperative patho-
logical examination.
The second significant prognostic factor in
multivariate analysis was patient gender. Male patients
have a 1.776 fold higher risk of death than women, and
a 1.897 higher risk of recurrence. The explanation of this
phenomenon warrants further analyses [6, 7, 13-15].
Patients with lymph node metastases pose as the
most important therapeutic problem in melanoma and
the target for adjuvant therapy. However, the results of
clinical trials with experimental drugs (e.g. interferon or
vaccines) are disappointing. Another technique used in
the adjuvant treatment of stage III melanoma is
radiotherapy. The literature data is controversial [16, 17],
but most of the authors suggest that the indication for
adjuvant radiotherapy may be multiple nodal metastases
or the presence of extracapsular extension. Although the
patients undergoing adjuvant radiotherapy as a selective
group demonstrated worse prognostic factors, they did
not show significant differences in OS and DFS as
compared to not irradiated patients. This implies the
survival benefit of adjuvant radiotherapy after radical
lymph node dissection due to melanoma metastases in
a selected group of patients.
In conclusion, our data suggests, that the most
important factor influencing patient outcome after
therapeutic LND due to regional basin lymph node
metastases is nodal extracapsular extension of melanoma
cells. The number of involved regional lymph nodes is
an important prognostic factor in patients without
extracapsular nodal invasion. There were no significant
differences in overall and disease-free survival for patients
treated, or not, with adjuvant radiotherapy after thera-
peutic LND although the patients undergoing adjuvant
radiotherapy as a selective group demonstrated worse
prognostic factors
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